Actively Recruiting
Development of a Clinical and Biological Database Monocentric and Prospective in Peritoneal Carcinosis
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-12
600
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers aim to improve understanding of peritoneal carcinosis, a type of cancer affecting the lining of the abdomen, to help develop targeted treatments. This study establishes a prospective clinical and biological database focused on this condition, collecting important biological samples and clinical data to support future research. Participants will provide blood and tissue samples at several key times: before any treatment, during surgeries, one month after surgeries, and if the disease progresses. These samples include both tumor and non-tumor tissues. Alongside this, clinical information will be systematically entered into a database at every surgery to track patient progress and outcomes. During the study, participants will undergo sample collections and clinical data recording. The main measure is the proportion of patients who consent to participate, tracked over four years. This process includes regular collection of biological materials and detailed clinical data, enabling ongoing research into the disease mechanisms and treatment development. The study is expected to continue until February 2038.
CONDITIONS
Brief Title
Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over the age of 18
- Diagnosed with peritoneal carcinosis from digestive origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer
- Eligible for treatment of peritoneal carcinosis, including surgery, chemotherapy, or other therapies
- Willing to participate in all study procedures including biological and tissue sample collection
- Able and willing to provide informed consent
You will not qualify if you...
- Not affiliated with the Social Protection system
- Unable to understand or comply with study instructions due to psychological, family, social, or geographical reasons
- Insufficient French language skills to consent and respond to questionnaires
- Under legal guardianship
- Pregnant or breastfeeding
- Treated in an emergency situation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 4 years or until study completion
Participants provide blood samples and tissue collections at specified times including before any treatment, at every surgery, one month after surgery, and at disease progression. Clinical data is also collected at every surgery.
Visits occur before treatment, at each surgery, one month after surgery, and at progression
Trial Site Locations
Total: 1 location
1
Institut du cancer de Montpellier ICM
Montpellier, France, 34298
Actively Recruiting
Research Team
A
Aurore MOUSSION
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here